Skip to main
ADUS

Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare (ADUS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Addus HomeCare is well-positioned to capitalize on the potential repeal of the 80/20 Medicaid Access rule and potential uptick in M&A activity. Their focus on developing and rolling out a next-generation caregiver app and Homecare Homebase system is expected to improve data visibility and optimize patient care. The company's organic census growth in the Hospice segment remains strong, but there are risks related to potential changes in Medicaid policies and reimbursement rates, as well as integration challenges from the Gentiva acquisition. Despite these risks, the company's solid financials and potential for improved census dynamics make it a solid investment option, with a Market Outperform rating and a price target of $142.

Bears say

Addus HomeCare is facing challenges in its Personal Care and Hospice segments due to regulatory scrutiny and a trend towards elevated oversight in the post-acute sector. Additionally, recent financial results have shown weakness, with consolidated revenue falling short of consensus estimates and weather negatively impacting revenue. The company's reliance on acquisitions for growth and potential impact from Medicare moratoria on new agency enrollment also add to the negative outlook. Despite average rate improvements in Personal Care, these factors may continue to affect the company's financial performance in the near future.

Addus HomeCare (ADUS) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Addus HomeCare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Addus HomeCare (ADUS) Forecast

Analysts have given Addus HomeCare (ADUS) a Buy based on their latest research and market trends.

According to 7 analysts, Addus HomeCare (ADUS) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $130.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $130.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Addus HomeCare (ADUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.